This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (K11)
Project #
5K11CA001498-04
Application #
3085863
Study Section
Cancer Institutional Fellowship Review Committee (CT)
Project Start
1990-08-01
Project End
1995-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Ott, G; Katzenberger, T; Siebert, R et al. (1998) Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 22:114-21
Croop, J M; Tiller, G E; Fletcher, J A et al. (1997) Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene 185:77-85
Xio, S; Li, D; Vijg, J et al. (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511-5
Xiao, S; Li, D; Corson, J M et al. (1995) Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55:2968-71
Fletcher, J A; Longtine, J; Wallace, K et al. (1995) Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer 12:220-3
Ashar, H R; Fejzo, M S; Tkachenko, A et al. (1995) Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82:57-65
Fletcher, J A; Naeem, R; Xiao, S et al. (1995) Chromosome aberrations in desmoid tumors. Trisomy 8 may be a predictor of recurrence. Cancer Genet Cytogenet 79:139-43
Naeem, R; Lux, M L; Huang, S F et al. (1995) Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 147:1553-8
Xiao, S; Renshaw, A; Cibas, E S et al. (1995) Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. Am J Pathol 147:896-904
Weremowicz, S; Kozakewich, H P; Haber, D et al. (1994) Identification of genetically aberrant cell lineages in Wilms' tumors. Genes Chromosomes Cancer 10:40-8

Showing the most recent 10 out of 25 publications